Logo image of MNPR

MONOPAR THERAPEUTICS INC (MNPR) Stock Overview

USA - NASDAQ:MNPR - US61023L2079 - Common Stock

81.67 USD
+5.77 (+7.6%)
Last: 9/30/2025, 4:30:00 PM
81.67 USD
0 (0%)
After Hours: 9/30/2025, 4:30:00 PM

MNPR Key Statistics, Chart & Performance

Key Statistics
52 Week High81.88
52 Week Low4.5
Market Cap503.90M
Shares6.17M
Float4.06M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-3.85
PEN/A
Fwd PEN/A
Earnings (Next)11-06 2025-11-06
IPO12-19 2019-12-19
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


MNPR short term performance overview.The bars show the price performance of MNPR in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 50 100 150

MNPR long term performance overview.The bars show the price performance of MNPR in the last 1, 2 and 3 years. 1 year 2 years 3 years 500 1K 1.5K 2K 2.5K

The current stock price of MNPR is 81.67 USD. In the past month the price increased by 140.7%. In the past year, price increased by 1671.58%.

MONOPAR THERAPEUTICS INC / MNPR Daily stock chart

MNPR Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 21.86 409.03B
AMGN AMGEN INC 12.94 151.93B
GILD GILEAD SCIENCES INC 14.34 137.73B
VRTX VERTEX PHARMACEUTICALS INC 23.12 100.41B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 59.77B
REGN REGENERON PHARMACEUTICALS 12.32 59.59B
ARGX ARGENX SE - ADR 79.56 45.14B
ONC BEONE MEDICINES LTD-ADR 5.96 40.50B
INSM INSMED INC N/A 30.44B
BNTX BIONTECH SE-ADR N/A 23.71B
NTRA NATERA INC N/A 22.09B
BIIB BIOGEN INC 8.75 20.54B

About MNPR

Company Profile

MNPR logo image Monopar Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing proprietary therapeutics for cancer patients. The company is headquartered in Wilmette, Illinois and currently employs 16 full-time employees. The company went IPO on 2019-12-19. The firm developing treatments for Wilson disease and novel radiopharmaceuticals for oncology. The Company’s product candidates are ALXN1840, MNPR-101, MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac. The Company’s Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Its radiopharmaceutical program consists of MNPR-101, a proprietary humanized monoclonal antibody that is being developed across multiple product candidates conjugated with different radioisotopes, for the treatment of advanced solid tumors. MNPR-101-Zr is the Company’s clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. MNPR-101-Lu is its clinical-stage radiotherapeutic comprised of MNPR-101 conjugated to lutetium-177. MNPR-101-Ac is late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.

Company Info

MONOPAR THERAPEUTICS INC

1000 Skokie Blvd Ste 350

Wilmette ILLINOIS 60091 US

CEO: Chandler Robinson

Employees: 15

MNPR Company Website

MNPR Investor Relations

Phone: 18473880349

MONOPAR THERAPEUTICS INC / MNPR FAQ

What is the stock price of MONOPAR THERAPEUTICS INC today?

The current stock price of MNPR is 81.67 USD. The price increased by 7.6% in the last trading session.


What is the ticker symbol for MONOPAR THERAPEUTICS INC stock?

The exchange symbol of MONOPAR THERAPEUTICS INC is MNPR and it is listed on the Nasdaq exchange.


On which exchange is MNPR stock listed?

MNPR stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for MONOPAR THERAPEUTICS INC stock?

13 analysts have analysed MNPR and the average price target is 83.9 USD. This implies a price increase of 2.72% is expected in the next year compared to the current price of 81.67. Check the MONOPAR THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is MONOPAR THERAPEUTICS INC worth?

MONOPAR THERAPEUTICS INC (MNPR) has a market capitalization of 503.90M USD. This makes MNPR a Small Cap stock.


How many employees does MONOPAR THERAPEUTICS INC have?

MONOPAR THERAPEUTICS INC (MNPR) currently has 15 employees.


What are the support and resistance levels for MONOPAR THERAPEUTICS INC (MNPR) stock?

MONOPAR THERAPEUTICS INC (MNPR) has a support level at 30.01. Check the full technical report for a detailed analysis of MNPR support and resistance levels.


Should I buy MONOPAR THERAPEUTICS INC (MNPR) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does MONOPAR THERAPEUTICS INC (MNPR) stock pay dividends?

MNPR does not pay a dividend.


When does MONOPAR THERAPEUTICS INC (MNPR) report earnings?

MONOPAR THERAPEUTICS INC (MNPR) will report earnings on 2025-11-06.


What is the Price/Earnings (PE) ratio of MONOPAR THERAPEUTICS INC (MNPR)?

MONOPAR THERAPEUTICS INC (MNPR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.85).


What is the Short Interest ratio of MONOPAR THERAPEUTICS INC (MNPR) stock?

The outstanding short interest for MONOPAR THERAPEUTICS INC (MNPR) is 3.62% of its float. Check the ownership tab for more information on the MNPR short interest.


MNPR Technical Analysis

ChartMill assigns a technical rating of 10 / 10 to MNPR. When comparing the yearly performance of all stocks, MNPR is one of the better performing stocks in the market, outperforming 99.71% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

MNPR Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to MNPR. MNPR has a great financial health rating, but its profitability evaluates not so good.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

MNPR Financial Highlights

Over the last trailing twelve months MNPR reported a non-GAAP Earnings per Share(EPS) of -3.85. The EPS decreased by -67.39% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -32.13%
ROE -33.16%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%30%
Sales Q2Q%N/A
EPS 1Y (TTM)-67.39%
Revenue 1Y (TTM)N/A

MNPR Forecast & Estimates

13 analysts have analysed MNPR and the average price target is 83.9 USD. This implies a price increase of 2.72% is expected in the next year compared to the current price of 81.67.


Analysts
Analysts80
Price Target83.9 (2.73%)
EPS Next Y56.81%
Revenue Next YearN/A

MNPR Ownership

Ownership
Inst Owners51.83%
Ins Owners4.72%
Short Float %3.62%
Short Ratio3.52